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A B S T R A C T   
Purpose: We report two patients who presented initially to ophthalmology clinics with symptoms and signs of 
orbital inflammation that led to a diagnosis of Erdheim-Chester Disease (ECD). 
Observations: ECD is a rare form of non-Langerhans cell histiocytosis (LCH) which is characterised by multi- 
system organ involvement and poor prognosis with standard therapies. Both patients were positive for the 
BRAF V600E mutation on genetic testing and were treated with the BRAF inhibitors Vemurafenib and Dabrafenib 
respectively. These cases highlight the variable clinical presentation and course of ECD, the classical radiological 
and histopathological findings, and the high degree of clinical suspicion necessary to reach this diagnosis. 
Conclusions and importance: The combination of xanthelasma and bilateral, diffuse intraconal orbital masses must 
suggest to the clinician the possibility of ECD; and consideration to arrange further investigation with a full body 
CT or FDG PET/CT scan should be given, even in the absence of wider systemic symptoms or signs. With the 
advent of targeted therapies such as BRAF inhibitors, it is of even more importance that a diagnosis of ECD is 
established in a timely manner in order to give these patients the best chance of reduced morbidity and increased 
survival.   
1. Introduction 
Erdheim-Chester Disease (ECD) is a rare form of non-Langerhans cell 
histiocytosis (LCH) characterised by multi-system xanthogranulomotous 
infiltration by lipid-laden histiocytes.1 It was first described in two cases 
by the pathologists Jakob Erdheim and William Chester in 1930.2 
Although there are now several hundred cases reported in the medical 
literature; there remains debate over the aetiology and pathogenesis of 
the disease. As of 2016, the World Health Organisation classified ECD as 
“a provisional entity under histiocytic and dendritic cell neoplasms, 
noting the association with B-rapidly accelerated fibrosarcoma gene 
(BRAF) mutations and the distinction from other members of the juve-
nile xanthogranuloma (JXG) family.3 
Aside from the aetiological uncertainties, the complexity of ECD is 
amplified by a highly variable clinical presentation and course, 
ranging from an indolent focal disease to life-threatening multi-organ 
failure.4 The rarity of the disease coupled with the aforementioned 
characteristics means that many of the current treatments are based 
on anecdotal evidence from small studies or individual case reports 
and the overall prognosis remains poor in cases with multi-organ 
involvement. 
ECD typically affects adults between the 5th and 7th decades with a 
relatively equal sex distribution. Histiocytic infiltration results in dense, 
progressive, recalcitrant fibrosclerosis of the bones, orbit and internal 
organs, including the mediastinal, pericardial, pleural, perinephric, and 
retroperitoneal spaces.5 From an ophthalmic perspective, orbital 
involvement in ECD is present in 27% of cases and is typically bilateral; 
often presenting as exophthalmos due to retro-orbital infiltration which 
is predominantly diffuse and intraconal.6 
We report two cases which presented initially to ophthalmology 
clinics with symptoms and signs of orbital inflammation. These cases 
highlight the variable clinical presentation and course of ECD, the 
classical radiological and histopathological findings, and the high de-
gree of clinical suspicion necessary to reach this diagnosis. Additionally, 
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they demonstrate the disparity in treatment response, both to standard 
treatments and to the novel BRAF inhibitors which have shown promise 
in recent years. 
2. Findings 
2.1. Case 1 
2.1.1. Initial presentation 
Our first case is a 49-year-old patient who presented to the 
Ophthalmology department in Norfolk and Norwich University Hospital 
in March 2016 with chronic headaches and recurrent pain and swelling 
around his left eye over the last year. On initial presentation, the ex-
amination showed a 3mm left sided proptosis with restriction of eye 
movements, high intraocular pressure (25 mmHg) and marked swelling 
and erythema of the eyelid. There was minimal swelling of the right 
eyelid with no other positive findings. At this point there were no sys-
temic symptoms and no xanthelasma, and reassuringly his vision at 
presentation was 6/6 in both eyes. 
2.1.2. Investigations 
Initial investigations showed a positive antinuclear antibody screen 
and bilateral intraconal masses on MRI imaging (Fig. 1A). Orbital biopsy 
showed CD3 positive T-cells and CD68 positive “foamy” macrophages 
and widespread collagenous fibrosis. The appearances at this point 
suggested an inflammatory process, but no clear cause. Despite a 
negative ANCA, the differential diagnosis at this point included gran-
ulomatosis with polyangiitis and the patient was started on high dose 
oral prednisolone (100mg od tapered down to 50mg over a few weeks). 
A lack of other symptoms and signs of wider systemic disease meant that 
histiocytic disorders such as ECD were not considered at this point in 
time. 
Over the next seven months the patient had multiple courses of oral 
prednisolone due to episodes of orbital inflammation causing significant 
periocular pain. Trials with azathioprine and cyclophosphamide were 
both unable to control the symptoms sufficiently nor allow weaning of 
the steroids. Despite the symptoms of orbital inflammation, the vision 
remained at 6/6 in both eyes, with full colour vision and visual fields, 
but still some mild disc swelling clinically. A full body CT revealed no 
lymphadenopathy, but did demonstrate pericardial thickening and 
effusion, as well as abnormal soft tissue surrounding both kidneys and 
bilateral hydronephrosis with peri-nephric fat stranding (Fig. 1B and C). 
Further investigation with PET CT demonstrated Fluorodeoxyglucose 
(FDG) avid orbital masses (Fig. 2). 
Fig. 2. Axial CT, FDG PET and fused PETCT images showing FDG avid bilateral orbital masses.  
Fig. 1. A: MRI demonstrating intraconal masses. B: CT abdomen demonstrating bilateral abnormal perirenal soft tissue and fat stranding. C: CT showing evidence of 
peri-aortitis. 
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In the context of orbital masses, vasculitis, and extensive pleural, 
peri-cardiac, renal, adrenal and mesenteric infiltration as well as the 
orbital biopsy reports; a diagnosis of ECD was made. 
2.1.3. Treatment 
Following the diagnosis, the symptoms continued to deteriorate with 
recurrent orbital inflammation and vision fluctuating between 6/6 and 
6/24. Further immunosuppressive treatment with methotrexate and 
mycophenolate mofetil was initiated in combination with systemic ste-
roids with little effect. Our patient in this case was identified as BRAF 
V600E mutation positive, and having failed to respond to four previous 
lines of therapy, in May 2017 (approximately 1 year after initial pre-
sentation) our patient was started on the BRAF inhibitor Vemurafenib 
960mg orally (po) twice daily (bd). 
Within one month of starting Vemurafenib the patient had complete 
cessation of episodes of orbital inflammation, and it was possible for the 
oral steroids to be weaned to 10mg once daily (od) without compro-
mising vision. Repeat PET scans also showed improvement in FDG ac-
tivity and no new lesions. 
Over the course of the next year the dose of Vemurafenib was 
steadily reduced and systemic steroids were completely weaned by 
December 2017. As of December 2018, there was no clinical evidence of 
orbital inflammation, and PET scan continues to show stable appear-
ances, in a metabolic complete remission, with no FDG activity in the 
intraconal masses or elsewhere. In June 2020 the patient remains clin-
ically stable, with visual acuity at baseline, and maintained on Vemur-
afenib 240mg po od. 
Fig. 3. OPTOS fundus photos at initial presentation demonstrating bilateral optic disc swelling.  
Fig. 4. FFA images at initial presentation showing leaky optic discs.  
Fig. 5. External photograph demonstrating the presence of bilateral Xanthelasma.  
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2.2. Case 2 
2.2.1. Initial presentation 
Our second case also presented to our outpatient department; but 
what followed was a distinctly more aggressive course of disease. This 
70-year-old patient presented in February 2019 following an optician 
referral of suspected optic neuritis with a two month history of painless, 
gradual reduction of vision in both eyes. He was systemically well and 
no other symptoms were elicited on systemic enquiry. 
On presentation the visual acuity [VA] was 6/15 in both eyes with a 
left relative afferent pupillary defect, bilaterally swollen optic discs and 
choroidal folds (Figs. 3 and 4). Baseline investigations showed non- 
specifically raised ESR (60 mm/hr) and CRP (73 mg/L) with no space 
occupying lesion reported on CT scan. Initial consideration was given to 
idiopathic inflammatory syndrome and oral steroids (Prednisolone 
60mg od) initiated. 
2.2.2. Investigations 
One month later the patient presented with further drop in vision of 
the left eye to 6/38 and xanthelasma was noted around both eyes 
(Fig. 5). Further blood tests including ANCA, TB, T. pallidium, Serum 
ACE, B12/Folate, and immunoglobulins were all unremarkable. An MRI 
Fig. 6. Initial MRI, Axial T1 slices shown here pre (left) and post (right) gadolinium enhancement demonstrating bilateral, diffuse, intraconal orbital masses.  
Fig. 7. A–B: CT scans with retroperitoneal inflammatory fat stranding involving the perirenal and periaortic spaces. C: Pre-treatment PET CT showing orbital uptake 
(red arrows), FDG avid bone lesions (yellow arrows), perineural and dural uptake (green arrows), periaortitis (purple arrow), peri renal disease and partial renal 
obstruction (blue arrows). D: post treatment PET CT showing complete metabolic response to treatment of all the previous findings except sclerotic bone infarcts in 
the distal femora, tibias and left calcaneum. 
J. Brodie et al.                                                                                                                                                                                                                                   
American Journal of Ophthalmology Case Reports 20 (2020) 100984
5
was arranged which showed bilateral intraconal orbital masses that 
were diffuse and homogenous (Fig. 6). 
At this point the differential diagnosis included: granulomatosis with 
polyangiitis, IgG4-related orbital inflammation, orbital lymphoma, and 
idiopathic orbital inflammatory disease. A referral was made to the 
rheumatology team who organised a full body CT, long bone x-rays and 
subsequent PET scan. These demonstrated aortitis, periaortitis, pleural 
involvement, osteosclerosis in the pelvic bones and tibia, and peri-
nephric fat stranding on both kidneys (Fig. 7 A–D). Concurrently an 
urgent orbital biopsy was arranged (May 2019) which revealed adipose 
tissue infiltrated by foamy histiocytes that were CD68 positive including 
touton-type multinucleated cells and scattered lymphocytes. No IgG4 
nor CD1a staining was noted. This constellation of radiological and 
histopathological findings led to a diagnosis of multi-system ECD in June 
2019 with widespread skeletal involvement, retroperitoneal disease, 
proteinuria, gross dependent oedema (serum albumin 13 g/L; normal 
range 35–50 g/L) and peri-orbital disease. Having been previously in-
dependent his WHO performance status was 3. 
2.2.3. Treatment 
Similar to case 1, our second patient tested BRAF positive and started 
treatment with interferon and steroids but continued to clinically dete-
riorate. In August 2019 he was commenced on the BRAF inhibitor 
Dabrafenib 150mg po bd, with immediate subjective improvement in his 
systemic symptoms, achieving a very good partial metabolic response on 
PET scan 2 months later. However, despite this treatment and high doses 
of systemic steroids the patient had already suffered a deterioration in 
his vision to no perception of light (NPL) and at his most recent follow up 
in June 2020, the patient remained NPL in both eyes, with improvement 
of his systemic symptoms, resolution of the dependent oedema, 
improvement in serum albumin (31 g/L) and improvement of his WHO 
performance status to 1. 
3. Discussion 
Diagnosis of ECD is often challenging because of its highly variable 
presentation and clinical course, multi-system involvement, and rarity 
of the disease. In terms of prognosis, morbidity, and mortality; CNS and 
cardiovascular involvement are the most significant.4 The most specific 
signs of ECD are the radiological and histological findings, but this 
means that a high degree of suspicion must be present in order to un-
cover them. 
3.1. A diagnostic challenge 
Given that orbital involvement and xanthelasma are present in 27% 
and 33% of cases respectively, and that exophthalmos is one of the most 
common presenting signs in patients with ECD; ophthalmologists are 
reasonably likely to be the first clinicians to encounter these cases.7 
Although much rarer; it is important for ophthalmologists to note that 
ECD can also present with intraocular involvement such as choroidal 
infiltrates with associated central serous retinal detachment and 
choroidal neovascular membrane.8 Our first patient presented with a 
combination of neurological symptoms (headache) and orbital signs 
including intermittent periocular pain and swelling and unilateral 
exophthalmos. In contrast, the disease in our second patient manifested 
as painless, gradual reduction in vision in both eyes due to orbital 
infiltration; and additionally, through the presence of xanthelasma of 
the eyelids. Both cases, however, were similarly devoid of other signs or 
symptoms of wider systemic disease. MRI scans in both patients revealed 
bilateral, diffuse, intraconal masses which is the typical finding in ECD 
patients with orbital infiltration. However, in the absence of systemic 
disease, the differential diagnosis of these pseudotumoural lesions was 
centred on granulomatosis with polyangiitis, IgG4-related orbital 
inflammation, orbital lymphoma, and idiopathic orbital inflammatory 
disease. A full body CT scan in both cases revealed the cluster of 
radiographic findings consistent with ECD: long bone osteosclerosis, 
perinephric stranding, periaortic infiltration, pleural involvement and 
pericardial effusion. 
One of the diagnostic criteria required for ECD is identification of 
xanthogranulomatous lesions characterised by CD68 (+)/CD1a (− ) 
histiocytes, often with mixed inflammation and fibrosis on a tissue bi-
opsy from an affected organ. However, there is considerable heteroge-
neity of histological appearances seen in ECD patients depending on the 
anatomical biopsy site, even in the same patient.9 In our first case, an 
orbital biopsy taken early in the disease course showed CD68 positive 
“foamy” macrophages and widespread collagenous fibrosis. The pa-
thology report at this point (taken in the context of orbital masses, but 
with no systemic involvement identified clinically or radiographically) 
suggested an inflammatory process, but identified no clear cause. It 
wasn’t until several months later when the radiographic findings were 
uncovered that a diagnosis of ECD was established. In contrast, the 
orbital biopsy in our second case also revealed adipose tissue infiltrated 
by foamy CD68 positive histiocytes; corroborating the already suspected 
diagnosis of ECD based on previous findings on imaging. Our experience 
in the first case demonstrates that a high degree of suspicion is necessary 
to establish a diagnosis of ECD – even when a biopsy demonstrates the 
typical histological findings. 
3.2. A mixed response to modern treatment 
The disease course in our first case was relatively indolent with ep-
isodes of pain associated with orbital inflammation intermittently 
affecting the patient for a year before initial presentation. Although 
there was mild unilateral proptosis present, there was no disturbance of 
visual acuity or visual field and this was maintained for approximately 
18 months following the onset of symptoms. The episodes of painful 
orbital inflammation were controlled with oral steroids, but there was 
no improvement of the manifestations of systemic infiltration despite 
treatment with multiple immunosuppressive agents. Treatment with a 
novel BRAF inhibitor (Vemurafenib) was commenced approximately 2 
years after onset of symptoms and resulted in reversal of visual loss and 
complete systemic improvement for this patient. 
In contrast, the disease course in our second patient was much more 
aggressive, having presented with a two month history of painless 
reduction of vision in both eyes which deteriorated to NPL vision 
within six months. In this case the time frame from presentation to 
suspected radiographic diagnosis of ECD was 6 weeks, with histo-
pathological confirmation following shortly thereafter. Despite treat-
ment with oral steroids and a novel BRAF inhibitor (Dabrafenib) we 
were not able to prevent the patient losing his vision from the focal 
orbital infiltration. However, treatment with the BRAF inhibitor has 
led to significant improvements in the patient’s systemic condition 
clinically and radiographically. 
In recent years, molecular profiling has allowed the identification of 
mutations along the mitogen activated protein kinase-extracellular 
signal regulated kinase (MAPK-ERK) pathway which has altered our 
understanding of the biology of ECD.10 The BRAFV600E mutation is the 
most clinically relevant mutation in ECD and is present in approximately 
57–75% of cases.11 As a result of these findings, ECD is now considered a 
clonal hematopoietic disorder marked by BRAFV600E and other MAPK 
pathway mutations, with clinical manifestations caused by neoplastic 
histiocytic infiltrates and uncontrolled inflammation.10 The discovery of 
this common BRAFV600E mutation (which is shared with hairy cell 
leukaemia and malignant melanoma) has led to the appropriation of 
targeted BRAF inhibitor therapies for use in ECD patients. 
Treatment of BRAFV600E-mutant ECD patients with these drugs has 
been shown to be effective in multiple case reports and case series, 
particularly in patients who have progressed despite other therapies.10 A 
recent cohort study demonstrated prolonged efficacy of Vemurafenib 
with a confirmed objective response rate of 54.5%; progression-free 
survival of 86% and overall survival of 96% at 2 years.12 Dabrafenib, 
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for which there are fewer reports in the literature in treating ECD, has 
also been used to good effect. In one case report it was used in combi-
nation with Trametinib (a MAPK inhibitor) to produce a progressive and 
sustained response in a patient with significant brain-stem disease and 
neurological symptoms.13 The authors of this case report chose Dabra-
fenib preferentially as it has shown improved overall survival without 
increased toxicity in clinical trials of melanoma treatment and improved 
CNS penetrance relative to Vemurafenib.13 There are currently no 
studies which have directly compared the efficacy of Vemurafenib and 
Dabrafenib in the treatment of ECD; but as demonstrated in our cases, 
both patients achieved a good clinical and radiological response to each 
of the drugs. 
4. Conclusions 
In summary we report two cases of BRAFV600E-mutant ECD which 
presented to our ophthalmology outpatient clinics over the course of the 
last three years. These cases highlight the variable clinical presentation 
and course of ECD, the classical radiological and histopathological 
findings, and the high degree of clinical suspicion necessary to reach this 
diagnosis. The combination of xanthelasma and bilateral, diffuse intra-
conal orbital masses must suggest to the clinician the possibility of ECD; 
and consideration to arrange further investigation with a full body CT or 
FDG PET/CT scan should be given, even in the absence of wider systemic 
symptoms or signs. With the advent of targeted therapies such as BRAF 
inhibitors, which have been shown to be highly efficacious, it is of even 
more importance that a diagnosis of ECD is established in a timely 
manner in order to give these patients the best chance of reduced 
morbidity and increased survival. 
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